论文部分内容阅读
目的:探讨阿德福韦酯治疗慢性乙肝的临床治疗效果。方法:对我院2012年2月至2013年1月收治的慢性乙肝患者临床治疗病例进行抽样,对40例慢性乙肝患者病例进行回顾性研究。观察患者乙肝指标前后变化、HBV-DNA、HBeAg转阴率、ALT复常率以及不良反应。结果:慢性乙肝患者经过治疗之后,患者乙肝指标前后指标变化、HBV-DNA、HBeAg转阴率、ALT复常率变化以及不良反应具有显著差异性,具备统计学意义(P<0.05)。结论:慢性乙肝患者采用阿德福韦酯治疗疗效确切,无严重不良反应,安全性较高,值得进行临床推广应用。
Objective: To investigate the clinical efficacy of adefovir dipivoxil in the treatment of chronic hepatitis B. Methods: The clinical treatment of chronic hepatitis B patients admitted to our hospital from February 2012 to January 2013 were sampled, and 40 cases of chronic hepatitis B patients were retrospectively studied. The change of HBV markers, HBV-DNA, HBeAg negative rate, ALT normalization rate and adverse reactions were observed. Results: After treatment, the changes of HBV markers, HBV-DNA, HBeAg negative rates, ALT normalization rate and adverse reactions in patients with chronic hepatitis B were significantly different (P <0.05). Conclusion: Adefovir dipivoxil treatment in patients with chronic hepatitis B has definite curative effect, no serious adverse reactions, high safety and worthy of clinical application.